USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT
Cited by 9
Related Papers
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2025|39